The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Topic summary

Second pass at: Manufacturer assistance programmes and their eligibility rules

This is a generated summary. It shows the 5 most-liked posts from a topic of 18, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.
JD
j.delacroixTL3Regular20 Jan 2025#1

Second pass at: Manufacturer assistance programmes and their eligibility rules — setting out what I have, and where I think it stops being reliable.

Two things I would like separated before anyone answers on Manufacturer assistance programmes, because they get bundled and then argued about as one thing.

The first is descriptive: what has actually been observed, by whom, and how. The second is causal: why. I am asking about the first only.

18 likes 18mo
HN
h.nicolaidesTL3Regular6 Feb 2025#4

The arithmetic in post #3 is right; the assumption feeding it is the part to check.

Worth stating the null on Manufacturer assistance programmes before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.

29 likes 18mo
KK
k.karlsenTL211 Feb 2025#5
p.onwuka, post #3: Discount programmes and coupons: manufacturers often offer coupons that reduce out-of-pocket costs if insurance is not covering or is covering at a high copay. These have eligibility restrictions but can save money. It is worth checking rather than assuming, which costs nothing. Go to post

A note on how Manufacturer assistance programmes gets discussed rather than on Manufacturer assistance programmes itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often.

14 likes in reply to #3 18mo
P
PSundbergTL2Member15 Mar 2025#14
sourced_claims, post #8: Narrowing post #7, because the general version has more than one answer. The most useful pricing posts here are the ones that show the arithmetic rather than the conclusion. Go to post

Coming back to post #10, because the follow-up matters more than the original answer.

On Manufacturer assistance programmes, the part that usually goes wrong is that the question is asked as though it has one answer. It has a range, and the width of the range is the interesting bit.

If you can post the two or three numbers you are working from, several people here will check the arithmetic rather than argue about the conclusion.

26 likes in reply to #8 16mo
AA
a.amankwahTL224 Mar 2025 · edited#17
k.karlsen, post #5: A note on how Manufacturer assistance programmes gets discussed rather than on Manufacturer assistance programmes itself: the confident posts get the replies and the careful ones get ignored, and the careful ones have been right more often. Go to post

What would change my mind on Manufacturer assistance programmes is a second dataset collected by someone with no stake in the first. Until then I hold it loosely and I would rather say so than pretend to more.

18 likes in reply to #5 16mo

Read the full topic (18 posts)

Suggested topics

TopicParticipantsRepliesViewsActivity
Pen wastage and its effect on real cost
Pen wastage and its effect on real cost Writing it up because I had to work it out twice and would rather nobody else did. Two things I would like separated before anyone answers on pen wastage, because they…
WVGPFYWMG+29 33 19k 21mo
Coming back to: Cost per delivered dose, which is the number that matters
On the subject in the title: Cost per delivered dose, which is the number that matters Working notes rather than a conclusion. Documenting an access outcome, dated, because everything in this category…
ILTVSDSCHD+6 10 2.5k 19mo
Why the cheapest option is often not the cheapest
Why the cheapest option is often not the cheapest I have a specific reason for asking rather than idle curiosity, and the context is below. Cheapest option: setting out the arithmetic in full, because I have…
ZIVOTMA+19 23 1.2k 12h
Pen wastage and its effect on real cost — the long version
Posting this under the heading it deserves: Pen wastage and its effect on real cost — the long version Everything below is what sits behind that. A narrow question about Pen wastage, deliberately narrow,…
EHAPSP 2 34k 13mo
List price versus negotiated price versus what you pay
On the subject in the title: List price versus negotiated price versus what you pay Working notes rather than a conclusion. List price versus negotiated price — I have the observation and I do not trust my…
JPJAVFVBCA+99 115 11k 3mo

Related topics — sharing the tags cost per milligram, data table, compounding

TopicParticipantsRepliesViewsActivity
Revisiting: Aggregates and why a purity assay may miss them entirely
Posting this under the heading it deserves: Revisiting: Aggregates and why a purity assay may miss them entirely Everything below is what sits behind that. I would like to disagree carefully with the settled…
LVNCOLNVMS+48 53 918 8mo
Cross-border purchase rules within the EU
On the subject in the title: Cross-border purchase rules within the EU Working notes rather than a conclusion. The question about cross-border purchase rules within that I actually want answered is the second…
HMEFVKGZA+45 49 15k 8mo
[2026 update] Why 99.2% and 97.8% on the same lot can both be correct
Why 99.2% and 97.8% on the same lot can both be correct — that is the question, and I have not found it answered plainly anywhere I have looked. I would like to understand what this number means before I…
BBWSZDSTD+1 5 719 2d
[2026 update] Reporting a disappointing outcome, and why it belongs here
On the subject in the title: Reporting a disappointing outcome, and why it belongs here Working notes rather than a conclusion. Proposing that Reporting a disappointing outcome deserves a maintained page…
KRSRCB 2 11k 8mo
State-level differences that actually matter
On the subject in the title: State-level differences that actually matter Working notes rather than a conclusion. The question about state-level differences that I actually want answered is the second one…
TPJVSRGVGE+6 10 56k 10mo